JOSHI M, BRULL R, KHETAWAT R, MACKINSON C, CAPLAN E; Interscience Conference on Antimicrobial Agents and Chemotherapy.
Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 2000 Sep 17-20; 40: 425.
R Adams Cowley Shock Trauma Ctr., Univ. of Maryland, Baltimore, MD
BACKGROUND: Polymicrobial nosocomial infections (NI) are a frequent problem in critically ill patients. Because causative organisms may not be known at the onset of NI, empiric broad-spectrum antibiotic therapy is instituted. As a result, colonization and infection with resistant organisms may occur. PIM has clinical activity against many GNR and demonstrates low rates of development of resistance in vitro. This study evaluates the susceptibility patterns of GNR and enterococci in SS obtained from critically ill patients during and after treatment with PIM.METHODS: Over a 2-year period, 2 SS, 1 taken within 6 days of initiation (SS1) and 1 within 5 days of discontinuation (SS2), were obtained from 41 patients treated with PIM for at least 7 days. Susceptibility to PIM, ciprofloxacin (CIP), piperacillin/tazobactam (P/T), gentamicin (GEN), and other antibiotics was measured for GNR. SS were also tested for vancomycin-resistant enterococci (VRE).RESULTS: 26 patients had resistant or intermediate-resistant organisms in SS1 or SS2. Four patients had the same resistant organism in both SS and are not included in this analysis [table: see text]. Conclusion: Low rates of resistance to cefepime therapy were found in GNR in SS during and after cefepime treatment. In addition, stool colonization by VRE was observed in only 1 patient.KEYWORDS: Cefepime; Resistance; VRE
Publication Types:
Keywords:
- Anti-Bacterial Agents
- Bacillus
- Cephalosporins
- Critical Illness
- Cross Infection
- Disease Susceptibility
- Enterococcus
- Feces
- Gram-Negative Bacteria
- Humans
- In Vitro
- Penicillanic Acid
- Piperacillin
- Streptococcus pneumoniae
- cefepime
- tazobactam
- therapy
Other ID:
UI: 102248727
From Meeting Abstracts